SCHEMBL357439

SCHEMBL357439

CCc1ccc(N2CCC(n3cc(F)c4c(Cl)ncnc43)CC2)nc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHIA Q9BZP6 3/20 0.40
LCAT P04180 1/20 0.35
GPR119 Q8TDV5 3/20 0.34
RIPK2 O43353 2/20 0.33
PDGFRB P09619 1/20 0.33
KIT P10721 1/20 0.33
SRC P12931 1/20 0.33
FLT3 P36888 1/20 0.33
SIK1 P57059 1/20 0.33
RIPK4 P57078 1/20 0.33
DDR1 Q08345 1/20 0.33
RIPK1 Q13546 1/20 0.33
DSTYK Q6XUX3 1/20 0.33
RIPK3 Q9Y572 1/20 0.33
HRH3 Q9Y5N1 1/20 0.32
LMNA P02545 1/20 0.32
HTT P42858 1/20 0.32
MEN1 O00255 1/20 0.32
CHI3L1 P36222 2/20 0.32
CHIT1 Q13231 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL356630 0.87 RIPK2 (0.40) CHIALCATGPR119RIPK2PDGFRB
SCHEMBL354786 0.87 GPR119 (0.40) GPR119
SCHEMBL356620 0.81 GPR119 (0.45) GPR119MEN1
SCHEMBL355724 0.78 GPR119 (0.40) GPR119RIPK2PDGFRBKITSRC
SCHEMBL357038 0.77 RIPK2 (0.38) GPR119RIPK2PDGFRBKITSRC
SCHEMBL358364 0.76 GPR119 (0.36) GPR119RIPK2PDGFRBKITSRC
SCHEMBL354783 0.76 RIPK2 (0.35) GPR119RIPK2PDGFRBKITSRC
SCHEMBL356929 0.76 MEN1 (0.39) RIPK2PDGFRBKITSRCFLT3
SCHEMBL354870 0.76 GPR119 (0.36) GPR119
SCHEMBL10172608 0.76 GPR119 (0.44) GPR119HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120016119-A1 NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-01-19 US disclosed
US-20120016119-A1 NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-01-19 US disclosed
US-20120016119-A1 NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-01-19 US disclosed
EP-2390254-A1 NOVEL PYRROLOÝ2,3-d¨PYRIMIDINE COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2011-11-30 EP disclosed
US-20110257678-A1 VASCULAR EMBOLIC FILTER EXCHANGE DEVICES AND METHODS OF USE THEREOF INCEPT LLC (US) 2011-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120016119-A1 NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND GPR119, GPR139, HCAR1 CHIA 3123/4885LCAT 1850/4885GPR119 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.